Pre-vaccination and early B cell signatures predict antibody response to SARS-CoV-2 mRNA vaccine.

Autor: Kardava L; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA., Rachmaninoff N; Multiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA., Lau WW; Multiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA., Buckner CM; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA., Trihemasava K; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA., de Assis FL; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA., Wang W; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA., Zhang X; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA., Wang Y; Institute for Bioscience and Biotechnology Research, Rockville, MD, USA., Chiang CI; Institute for Bioscience and Biotechnology Research, Rockville, MD, USA., Narpala S; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA., Reger R; Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD, USA., McCormack GE; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA., Seamon CA; Critical Care Medicine Department, National Institutes of Health Clinical Center, NIH, Bethesda, MD, USA., Childs RW; Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD, USA.; United States Public Health Service Commissioned Corps, Rockville, MD, USA., Suffredini AF; Critical Care Medicine Department, National Institutes of Health Clinical Center, NIH, Bethesda, MD, USA., Strich JR; Critical Care Medicine Department, National Institutes of Health Clinical Center, NIH, Bethesda, MD, USA.; United States Public Health Service Commissioned Corps, Rockville, MD, USA., Chertow DS; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.; Critical Care Medicine Department, National Institutes of Health Clinical Center, NIH, Bethesda, MD, USA.; United States Public Health Service Commissioned Corps, Rockville, MD, USA., Davey RT; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA., Sneller MC; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA., O'Connell S; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA., Li Y; Institute for Bioscience and Biotechnology Research, Rockville, MD, USA.; Department of Microbiology and Immunology and Center for Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, MD, USA., McDermott A; Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA., Chun TW; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA., Fauci AS; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA., Tsang JS; Multiscale Systems Biology Section, Laboratory of Immune System Biology, NIAID, NIH, Bethesda, MD, USA.; NIH Center for Human Immunology, NIAID, NIH, Bethesda, MD, USA., Moir S; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Jazyk: angličtina
Zdroj: MedRxiv : the preprint server for health sciences [medRxiv] 2021 Jul 07. Date of Electronic Publication: 2021 Jul 07.
DOI: 10.1101/2021.07.06.21259528
Abstrakt: SARS-CoV-2 mRNA vaccines are highly effective, although weak antibody responses are seen in some individuals with correlates of immunity that remain poorly understood. Here we longitudinally dissected antibody, plasmablast, and memory B cell (MBC) responses to the two-dose Moderna mRNA vaccine in SARS-CoV-2-uninfected adults. Robust, coordinated IgA and IgG antibody responses were preceded by bursts of spike-specific plasmablasts after both doses, but earlier and more intensely after dose two. Distinct antigen-specific MBC populations also emerged post-vaccination with varying kinetics. We identified antigen non-specific pre-vaccination MBC and post-vaccination plasmablasts after dose one and their spike-specific counterparts early after dose two that correlated with subsequent antibody levels. These baseline and response signatures can thus provide early indicators of serological efficacy and explain response variability in the population.
Databáze: MEDLINE